Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Hepatology

• Publication date

  2009-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/hep.23116PMID 19670459
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recent advances in nonalcoholic fatty liver disease

  2009cited by this paper
• New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)

  2009cited by this paper
• The Epidemic of Type 2 Diabetes Mellitus: Its Links to Obesity, Insulin Resistance, and Lipotoxicity

  2009cited by this paper
• Thiazolidinediones in NASH. An odd couple meant to be?

  2009cited by this paper
• Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial.

  2008cited by this paper
• Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects.

  2008cited by this paper
• Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.

  2008cited by this paper
• Chronic low-dose lipid infusion in healthy patients induces markers of endothelial activation independent of its metabolic effects.

  2008cited by this paper
• Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis.

  2008cited by this paper
• Recent advances in nonalcholic fatty liver disease

  2008cited by this paper
• Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.

  2007cited by this paper
• Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver

  2007cited by this paper
• Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.

  2007cited by this paper
• Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes.

  2007cited by this paper
• Inflammation in Diabetes Mellitus: Role of Peroxisome Proliferator-Activated Receptor–α and Peroxisome Proliferator-Activated Receptor–γ Agonists

  2007cited by this paper
• Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance

  2006cited by this paper
• Nonalcoholic steatohepatitis: a twenty-first century epidemic?

  2006cited by this paper
• The Effect of Pioglitazone on the Liver

  2006cited by this paper
• Therapy of NAFLD: insulin sensitizing agents.

  2006cited by this paper
• Contributions of different fatty acid sources to very low-density lipoprotein-triacylglycerol in the fasted and fed states.

  2006cited by this paper
• Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it.

  2006cited by this paper
• A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.

  2006cited by this paper
• Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?

  2005cited by this paper
• Adiponectin: a relevant player in PPARγ-agonist-mediated improvements in hepatic insulin sensitivity?

  2005cited by this paper
• Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.

  2005cited by this paper
• Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo.

  2005cited by this paper
• Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms

  2005cited by this paper
• Lessons from animal models of NASH.

  2005cited by this paper
• Mitochondria in nonalcoholic fatty liver disease.

  2004cited by this paper
• A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.

  2004cited by this paper
• Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes.

  2004cited by this paper
• Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes.

  2004cited by this paper
• Molecular mediators of hepatic steatosis and liver injury.

  2004cited by this paper
• The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo.

  2004cited by this paper
• Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach.

  2004cited by this paper
• Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.

  2004cited by this paper
• A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

  2004cited by this paper
• Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR‐γ ligand rosiglitazone

  2003cited by this paper
• A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes.

  2003cited by this paper
• Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase

  2002cited by this paper
• Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men.

  2002cited by this paper
• Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

  2001cited by this paper
• Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects.

  2001cited by this paper
• Nonalcoholic fatty liver disease: a feature of the metabolic syndrome.

  2001cited by this paper
• Stage-specific effects of a thiazolidinedione on proliferation, differentiation and PPARgamma mRNA expression in 3T3-L1 adipocytes.

  2001cited by this paper
• Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

  2001cited by this paper
• A dominant-negative peroxisome proliferator-activated receptor gamma (PPARgamma) mutant is a constitutive repressor and inhibits PPARgamma-mediated adipogenesis.

  2000cited by this paper
• Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists.

  2000cited by this paper
• A Dominant-negative Peroxisome Proliferator-activated Receptor γ (PPARγ) Mutant Is a Constitutive Repressor and Inhibits PPARγ-mediated Adipogenesis*

  2000cited by this paper
• Treatment of insulin resistance with peroxisome proliferator–activated receptor γ agonists

  2000cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids.

  1997cited by this paper
• Lipotoxicity in the Pathogenesis of Obesity-Dependent NIDDM: Genetic and Clinical Implications

  1995cited by this paper
• Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance.

  1989cited by this paper

• Associations of adipose tissue insulin resistance with fasting blood glucose and HbA1c in adults without diabetes.

  2026cites this paper
• The Role of Kupffer Cells and Liver Macrophages in the Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease

  2026cites this paper
• Association between HOMA-IR and metabolic dysfunction-associated steatohepatitis in U.S. adults with MASLD

  2025cites this paper
• Improving MASLD Risk Stratification in Young Adults with Cardiometabolic Risk Factors and Insulin Resistance Assessment

  2025cites this paper
• Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial

  2025influential citation
• MASH: the nexus of metabolism, inflammation, and fibrosis

  2025influential citation
• NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): DISEASE MECHANISMS AND CONTEMPORARY THERAPEUTIC APPROACHES - A LITERATURE REVIEW

  2025cites this paper
• Bariatric Surgery Impact on Women with Polycystic Ovary Syndrome: A Prospective Cohort Study

  2025cites this paper
• Prevention of type 2 diabetes through prediabetes remission without weight loss

  2025cites this paper
• Microneedle–nanoparticle hybrid platforms for metabolic syndrome: advances in point-of-care diagnostics and transdermal therapeutics

  2025cites this paper
• Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction– Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With Tirzepatide

  2025cites this paper
• Microbiota encroachment and a gut-adipose-liver axis in metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Glucagon‐like peptide‐1 is involved in fasting and postprandial blood flow regulation of subcutaneous adipose tissue

  2025cites this paper
• The regulation of fatty acid mobilization is extravagant rather than frugal - a perspective indicating a limitation of the thrifty genotype hypothesis.

  2025cites this paper
• Relationship Between Aerobic Fitness and Adipose Tissue Insulin Resistance.

  2025cites this paper
• Mixed-meal challenge differentially modulates metabolic pathways in adipose tissue in healthy abdominally obese subjects with high versus low liver fat: a secondary analysis of a randomized clinical trial

  2025cites this paper
• Adipose tissue insulin resistance in young Japanese women is associated with metabolic abnormalities and dehydroepiandrosterone-sulfate

  2024cites this paper
• To compare the HOMA-IR and metabolic profile in lean and obese subjects with non-alcoholic fatty liver disease

  2024cites this paper
• The DNA methyltransferase inhibitor decitabine blunts the response to a high-animal fat and protein diet in mice

  2024cites this paper
• Associations between sensitivity to thyroid hormones and insulin resistance in euthyroid adults with obesity

  2024cites this paper
• 6-Gingerol alleviates ectopic lipid deposition in skeletal muscle by regulating CD36 translocation and mitochondrial function.

  2024cites this paper
• Therapeutic Role of Bone Marrow Mesenchymal Stem Cells (BMSCs) in Nonalcoholic Steatohepatitis (NASH) Cirrhosis.

  2024cites this paper
• Sex differences in adipose insulin resistance are linked to obesity, lipolysis and insulin receptor substrate 1

  2024cites this paper
• Lipid metabolism in MASLD and MASH: From mechanism to the clinic

  2024cites this paper
• Clusters of adipose tissue dysfunction in adults with type 2 diabetes identify those with worse lipidomic profile despite similar glycaemic control

  2024cites this paper
• Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen

  2024cites this paper
• Screening of Metabolic-Associated Fatty Liver Disease in General Population Attending Outpatient Clinic

  2024cites this paper
• The pan-PPAR agonist lanifibranor improves cardiometabolic health in patients with metabolic dysfunction-associated steatohepatitis

  2024cites this paper
• Hepatic glucose metabolism in the steatotic liver

  2024cites this paper
• Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)

  2024cites this paper
• Adipocyte hypertrophy associates with in vivo postprandial fatty acid metabolism and adipose single-cell transcriptional dynamics

  2023cites this paper
• Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid

  2023cites this paper
• Curative role of natural PPARγ agonist in non-alcoholic fatty liver disease (NAFLD)

  2023cites this paper
• Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus

  2023cites this paper
• Effect of Canagliflozin on liver steatosis in obese non diabetic patients with non-alcoholicfatty liver disease: A double blind randomized controlled trial

  2023cites this paper
• Correlation between serum uric acid and body fat distribution in patients with MAFLD

  2023cites this paper
• Mechanisms of weight loss-induced remission in people with prediabetes: a post-hoc analysis of the randomised, controlled, multicentre Prediabetes Lifestyle Intervention Study (PLIS).

  2023cites this paper
• Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis

  2023cites this paper
• An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease.

  2023cites this paper
• Adipose tissue dysfunction serum markers are associated with high density lipoprotein size and glycation in the early stages of type 2 diabetes

  2023cites this paper
• Visceral adipose tissue is an independent predictor and mediator of the progression of coronary calcification: a prospective sub-analysis of the GEA study

  2023cites this paper
• Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease.

  2023cites this paper
• Evaluation of PXL065 - Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1).

  2023cites this paper
• Sedentary Time Is Independently Related to Adipose Tissue Insulin Resistance in Adults With or at Risk of Type 2 Diabetes

  2023cites this paper
• PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.

  2023cites this paper
• Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials

  2023cites this paper
• Reduced Growth Hormone Predicts Worsening Adipose Tissue Insulin Resistance in Adults with Obesity

  2023cites this paper
• Benefits of Combining Sonchus brachyotus DC. Extracts and Synbiotics in Alleviating Non-Alcoholic Fatty Liver Disease

  2023cites this paper
• Adipose Tissue Insulin Resistance Is Positively Associated With Serum Uric Acid Levels and Hyperuricemia in Northern Chinese Adults

  2022cites this paper
• The effect of exercise training on adipose tissue insulin sensitivity: A systematic review and meta‐analysis

  2022cites this paper
• Obesity-Related Insulin Resistance: The Central Role of Adipose Tissue Dysfunction.

  2022cites this paper
• A Quantitative Systems Pharmacology Model of Liver Lipid Metabolism for Investigation of Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients with Type 2 Diabetes and NAFLD.

  2022cites this paper
• Lactation alters the relationship between liver lipid synthesis and hepatic fat stores in the postpartum period

  2022influential citation
• BMP4 and Gremlin 1 regulate hepatic cell senescence during clinical progression of NAFLD/NASH

  2022cites this paper
• Randomized clinical trial: effect of low-dose flutamide on abdominal adipogenic function in normal-weight women with polycystic ovary syndrome.

  2022cites this paper
• An Insight Into the Association of Sclerostin With Insulin Sensitivity and Glycemic Parameters in Male Indian Prediabetic and Diabetic Population

  2022cites this paper
• Albumin knockout mice exhibit reduced plasma free fatty acid concentration and enhanced insulin sensitivity

  2022cites this paper
• Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment

  2022cites this paper
• DMSO_A_291350 1117..1128

  2021cites this paper
• Ursolic acid ameliorates adipose tissue insulin resistance in aged rats via activating the Akt-glucose transporter 4 signaling pathway and inhibiting inflammation.

  2021cites this paper
• Coordinated regulation of gene expression and microRNA changes in adipose tissue and circulating extracellular vesicles in response to pioglitazone treatment in humans with type 2 diabetes

  2021cites this paper
• Association between new markers of cardiovascular risk and hepatic insulin resistance in those at high risk of developing type 2 diabetes

  2021cites this paper
• Pharmacology of NASH

  2021cites this paper
• A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.

  2021cites this paper
• Serum Testosterone to Androstenedione Ratio Predicts Metabolic Health in Normal-Weight Polycystic Ovary Syndrome Women

  2021cites this paper
• Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests

  2021cites this paper
• Free fatty acids, glicentin and glucose-dependent insulinotropic polypeptide as potential major determinants of fasting substrate oxidation

  2021cites this paper
• Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease

  2021influential citation
• Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial.

  2021cites this paper
• Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study

  2021cites this paper
• Ursolic acid ameliorates adipose tissue insulin resistance in aged rats via activating the Akt‑glucose transporter 4 signaling pathway and inhibiting inflammation

  2021cites this paper
• Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review

  2021cites this paper
• Adipose Tissue Insulin Resistance Is Longitudinally Associated With Adipose Tissue Dysfunction, Circulating Lipids, and Dysglycemia: The PROMISE Cohort

  2021cites this paper
• Adipose Tissue Insulin Resistance is Closely Associated with Metabolic Syndrome in Northern Chinese Populations

  2021cites this paper
• Non-invasive Methods in Diagnosis of Nonalcoholic Fatty Liver Disease

  2021cites this paper
• The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

  2021cites this paper
• Insulin Action, Glucose Homeostasis and Free Fatty Acid Metabolism: Insights From a Novel Model

  2021cites this paper
• PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

  2021cites this paper
• Non-alcoholic fatty liver disease: A patient guideline

  2021cites this paper
• Pharmacological Options for NASH

  2020cites this paper
• A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.

  2020cites this paper
• Adipose tissue-liver cross talk in the control of whole-body metabolism: implications in non-alcoholic fatty liver disease.

  2020cites this paper
• Non-Alcoholic Fatty Liver Disease: A 360-degree Overview

  2020cites this paper
• NAFLD and Insulin Resistance: A Multisystemic Disease

  2020cites this paper
• Relationship of obesity to adipose tissue insulin resistance

  2020cites this paper
• Serum glypican4 and glycosylphosphatidylinositol-specific phospholipase D levels are associated with adipose tissue insulin resistance in obese subjects with different glucose metabolism status

  2020cites this paper
• Improvement in Insulin Resistance and Estimated Hepatic Steatosis and Fibrosis after Endoscopic Sleeve Gastroplasty.

  2020cites this paper
• Administration of small-molecule guanabenz acetate attenuates fatty liver and hyperglycemia associated with obesity

  2020cites this paper
• Metabolic Footprint, towards Understanding Type 2 Diabetes beyond Glycemia

  2020cites this paper
• Serum ZAG and Adiponectin Levels Were Closely Related to Obesity and the Metabolically Abnormal Phenotype in Chinese Population

  2020cites this paper
• The COVID-19 Pandemic during the Time of the Diabetes Pandemic: Likely Fraternal Twins?

  2020cites this paper
• Hyperglycemia-stimulating diet induces liver steatosis in sheep

  2020cites this paper
• Therapeutic landscape for NAFLD in 2020.

  2020cites this paper
• Determinants and correlates of adipose tissue insulin resistance index in Japanese women without diabetes and obesity

  2020cites this paper
• Immunological mechanisms and therapeutic targets of fatty liver diseases

  2020cites this paper
• Towards precision medicine: defining and characterizing adipose tissue dysfunction to identify early immunometabolic risk in symptom-free adults from the GEMM family study

  2020influential citation
• Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.

  2020cites this paper
• Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis

  2020cites this paper
• Relation of the degree of obesity in childhood to adipose tissue insulin resistance

  2019cites this paper